{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:30:26Z","timestamp":1792553426496,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejca.2025.115427","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T14:48:31Z","timestamp":1744728511000},"page":"115427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin"],"prefix":"10.1016","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0350-1703","authenticated-orcid":false,"given":"Samy","family":"Belka\u00efd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0054-0624","authenticated-orcid":false,"given":"Emmanuel","family":"Ribereau-Gayon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4655-6867","authenticated-orcid":false,"given":"Sylvie","family":"Chabaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Anriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibald","family":"Chalas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Fl\u00e9chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4455-557X","authenticated-orcid":false,"given":"Armelle","family":"Vinceneux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"B\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6001-164X","authenticated-orcid":false,"given":"Gilles","family":"Freyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Darnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Tartas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Amini-Adle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115427_bib1","doi-asserted-by":"crossref","DOI":"10.1007\/s40262-024-01369-0","article-title":"Clinical pharmacology of the antibody\u2013drug conjugate enfortumab vedotin in advanced urothelial carcinoma and other malignant solid tumors","author":"Tang","year":"2024","journal-title":"Clin Pharm"},{"key":"10.1016\/j.ejca.2025.115427_bib2","article-title":"Therapeutic prospects of nectin-4 in cancer: applications and value","volume":"14","author":"Li","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2025.115427_bib3","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115427_bib4","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115427_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.euf.2024.04.001","article-title":"Biomarkers of response to anti-NECTIN4 antibody-drug conjugate enfortumab vedotin in urothelial cancer","author":"Kl\u00fcmper","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.ejca.2025.115427_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1069356","article-title":"Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma","volume":"12","author":"Fenton","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2025.115427_bib7","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Kl\u00fcmper","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.115427_bib8","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1158\/1078-0432.CCR-22-3882","article-title":"Scratching the surface: NECTIN-4 as a surrogate for enfortumab vedotin resistance","volume":"29","author":"Aggen","year":"2023","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2025.115427_bib9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.eururo.2022.12.009","article-title":"In patients with advanced urothelial carcinoma, immune checkpoint inhibition prior to enfortumab vedotin is associated with high-grade skin toxicity","volume":"83","author":"Molina","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2025.115427_bib10","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1111\/1346-8138.16646","article-title":"Cutaneous toxicity with suprabasal blisters and dyskeratosis following administration of enfortumab vedotin","volume":"50","author":"Hasui","year":"2023","journal-title":"J Dermatol"},{"key":"10.1016\/j.ejca.2025.115427_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jdcr.2021.05.020","article-title":"Cutaneous reactions with enfortumab vedotin: a case series and review of the literature","volume":"14","author":"Dobry","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.ejca.2025.115427_bib12","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1111\/jdv.19454","article-title":"Skin toxicity of enfortumab vedotin: proposal of a specific management algorithm","volume":"38","author":"Ingen-Housz-Oro","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2025.115427_bib13","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of dermatologic events associated with the nectin-4-directed antibody-drug conjugate enfortumab vedotin","volume":"27","author":"Lacouture","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2025.115427_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.621591","volume":"11","author":"Viscuse","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2025.115427_bib15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of cutaneous immune-related adverse events with increased survival in patients treated with anti\u2013programmed cell death 1 and anti\u2013programmed cell death ligand 1 therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2025.115427_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1377842","article-title":"Enfortumab vedotin-related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience","volume":"14","author":"Vlachou","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2025.115427_bib17","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.21873\/anticanres.17115","article-title":"Cutaneous and renal toxicities of enfortumab vedotin for advanced urothelial carcinoma: the UROKYU study","volume":"44","author":"Furubayashi","year":"2024","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2025.115427_bib18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.euros.2023.01.002","article-title":"Enfortumab vedotin\u2013related cutaneous toxicity and radiographic response in patients with urothelial cancer: a single-center experience and review of the literature","volume":"49","author":"Vlachou","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.ejca.2025.115427_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jdcr.2024.02.003","article-title":"Desquamative extravasation reaction secondary to enfortumab vedotin","volume":"46","author":"Pulavarty","year":"2024","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.ejca.2025.115427_bib20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdcr.2023.10.025","article-title":"Enfortumab vedotin toxic epidermal necrolysis\u2013like blistering dermatosis: a case series and review of the literature","volume":"43","author":"Khanjar","year":"2023","journal-title":"JAAD Case Rep"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925002084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925002084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T11:57:57Z","timestamp":1749815877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925002084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":20,"alternative-id":["S0959804925002084"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115427","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115427","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115427"}}